- Associated Press•9 hours ago
Albany Molecular Research Inc. on Tuesday reported a fourth-quarter loss of $15.4 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Albany, New York-based company ...
- PR Newswire•10 hours agoAMRI Announces Agreement with Accord Healthcare to Jointly Develop, Manufacture and Commercialize Parenteral Drug Products
ALBANY, N.Y., Feb. 21, 2017 /PRNewswire/ -- AMRI (AMRI) today announced that it has entered into an agreement with the pharmaceutical group Ferrer and Accord Healthcare, Inc. ("Accord Healthcare") to jointly develop and manufacture an undisclosed complex parenteral drug product for registration and subsequent commercialization in the United States with the option to partner on additional drug products. Under terms of the agreement, AMRI will work with Ferrer to develop and initially provide cGMP manufacturing and analytical support for the registration of the new product. Accord Healthcare will be responsible for advancing the product candidate through regulatory submission and commercialization.
- PR Newswire•10 hours ago
ALBANY, N.Y., Feb. 21, 2017 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the fourth quarter and full year ended December 31, 2016 and provided an outlook for 2017. ...
AMRI : Summary for Albany Molecular Research, Inc. - Yahoo Finance
Albany Molecular Research, Inc. (AMRI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||6.76 x 1000|
|Ask||16.78 x 7000|
|Day's Range||15.60 - 17.58|
|52 Week Range||12.45 - 19.35|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-11.22|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|